IRulya Therapeutics Inc. SEC filings IRLA
IRulya Therapeutics Inc. has 462 filings in SEC EDGAR's recent list, going back to Jan 5, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 2, 2026 | — |
| DEF 14A | Proxy statement | Aug 25, 2026 | Oct 6, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2026 | Jul 31, 2026 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 11, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 4, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 5, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2024 | Jun 5, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEF 14A | Proxy statement | Apr 14, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 4, 2023 | — |
| DEFA14A | Additional proxy material | May 25, 2022 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 16, 2021 |
| DEFA14A | Additional proxy material | Apr 22, 2020 | — |
| DEF 14A | Proxy statement | Apr 22, 2020 | Jun 8, 2020 |
Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IRLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662774
- Former names
- Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.